{"disease":{"id":"oligoprogression","name":"oligoprogression"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05784428","title":"Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression","phase":"NA","overall_status":"RECRUITING","enrollment_count":598,"lead_sponsor_name":"Robert Olson","has_results":false},{"nct_id":"NCT06918951","title":"Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT06592612","title":"Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07121335","title":"SMC Radiation Oncology SABR Cohort for Oligometastasis","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06489821","title":"STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Juravinski Cancer Center","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}